药品许可交易：2019-2025

本报告研究了药品许可情势，并对公司如何以及为何签订许可协议进行了深入的理解和分析。

这份经过全面修订和更新的报告提供了 2019 年至 2025 年许可协议的详细资讯。

此报告提供双方宣布的授权协议的付款条款。这些数据为了解付款条款和其他合约条件提供了宝贵的见解。

主要优点：

本报告为读者提供了以下主要好处：

• 了解 2019 年及以后的合约趋势
• 浏览许可机会
• 基准分析：确定交易的市场价值
• 财务条款：预付款、里程碑付款、特许权使用费
• 按公司 (AZ)、治疗领域和技术类型查看合约目录
• 您可以查看主要交易金额
• 看看谁是最活跃的交易者
• 确定每份合约的资产和条款
• 存取合约文件：深入了解合约结构
• 尽职调查：评估拟议合约条款是否适合您的业务
• 节省数百小时的研究时间

调查范围

• 生物製药产业授权协议的趋势
• 许可协议结构概述
• 涵盖製药和生物技术的授权协议记录目录
• 以价值计算的主要授权协议
• 最活跃的授权交易撮合者
• 关键许可合作伙伴资源

目录

摘要整理

第1章 简介

第2章 授权契约趋势

• 授权契约定义
• 2019年以后的授权契约趋势
  • 授权契约趋势:各年度
  • 授权契约:各开发阶段
  • 授权契约:各产品部门
  • 授权契约:各治疗领域
  • 授权契约:各技术类型
  • 授权契约:最活跃的企业
• 为什么要签授权协议？
• 许可协议的未来

第3章 授权契约结构:概要

• 授权契约结构

第4章 主要授权契约

• 首位授权契约:各金额

第5章 25 家最活跃的授权承包商

• 25 家最活跃的许可承包商

第6章 含契约名录的授权契约

• 2019-2025年的契约伴随的授权契约
• 契约名录
• 契约名录- 授权契约:各企业(A-Z)
• 契约名录- 授权契约:各治疗领域
• 契约名录- 许可证lie契约:各技术类型
• 关于Biopharma Research
• 目前联盟
• 目前协定
• Current 来自Partnering的最近的报告标题

Licensing Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter licensing deals.

Fully revised and updated, the report provides details of licensing deals from 2019 to 2025.

The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals.

Chapter 4 provides a review of the leading licensing deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.

The deal directory includes a comprehensive listing of all licensing deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2019.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.

Key benefits

Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Licensing Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.

Licensing Deals in Pharmaceuticals includes:

• Trends in licensing dealmaking in the biopharma industry
• Overview of licensing deal structure
• Directory of licensing deal records covering pharmaceutical and biotechnology
• The leading licensing deals by value
• Most active licensing dealmakers
• The leading licensing partnering resources

In Licensing Deals in Pharmaceuticals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Licensing Deals in Pharmaceuticals provides comprehensive access to available records for licensing deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2019
  • 2.3.1. Licensing dealmaking by year, 2019-2025
  • 2.3.2. Licensing dealmaking by phase of development, 2019-2025
  • 2.3.3. Licensing dealmaking by industry sector, 2019-2025
  • 2.3.4. Licensing dealmaking by therapy area, 2019-2025
  • 2.3.5. Licensing dealmaking by technology type, 2019-2025
  • 2.3.6. Licensing dealmaking by most active company, 2019-2025
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts 2019-2025
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements, 2019-2025
• Figure 3: Licensing deals signed at each phase of development, 2019-2025
• Figure 4: Licensing deals by industry sector, 2019-2025
• Figure 5: Licensing deals by therapy area, 2019-2025
• Figure 6: Licensing deals by technology type, 2019-2025
• Figure 7: Top 25 most active licensing dealmakers, 2019-2025
• Figure 8: Top licensing deals by value, 2019-2025
• Figure 9: Most active licensing dealmakers, 2019-2025